Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback